Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816400 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00816400 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 49 participants.
The verdict
NCT00816400, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Evaluate the safety, tolerability and the tolerated maximum dose of MEDI-575 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
Interventions
- DRUG MEDI-575
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-03-02 |
| Est. Completion | 2012-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00816400
The ClinicalTrials.gov registry entry for NCT00816400 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI-575 is the first listed.
NCT00816400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00816400 about?
NCT00816400 is a clinical study titled "A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.". Evaluate the safety, tolerability and the tolerated maximum dose of MEDI-575 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
What is the current status of trial NCT00816400?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2009-03-02. Estimated completion is 2012-01-19.
What interventions are being tested in trial NCT00816400?
The interventions under investigation include: MEDI-575 (DRUG).
Who is sponsoring clinical trial NCT00816400?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.